Tirzepatide Research
Product image coming soon
Tirzepatide: Dual GIP/GLP-1 Receptor Agonist Research Profile
Tirzepatide is a synthetic dual glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1 receptor (GLP-1R) agonist studied in laboratory settings for its role in incretin receptor pharmacology and metabolic signalling research. Its development represented a significant step beyond single GLP-1R agonists, demonstrating enhanced metabolic effects through simultaneous activation of two distinct incretin receptors.
Tirzepatide: Dual GIP/GLP-1R Agonism
Chemical and Molecular Data
| Property | Value |
|---|---|
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813.46 g/mol |
| CAS number | 2023788-19-2 |
| Drug class | Dual GIP/GLP-1 receptor agonist |
| Purity | greater than or equal to 98% as verified by HPLC |
| Form | Lyophilised powder |
| Storage | -20 degrees C, protected from light and moisture |
| Reconstitution | Bacteriostatic water recommended |
Tirzepatide: Dual GIP/GLP-1R Agonism
Structural Features
Tirzepatide is a 39-amino-acid peptide based on the native GIP sequence with modifications for GLP-1R activity. A C20 fatty diacid is attached via a mini-PEG linker to the epsilon-amino group of Lys26, enabling albumin binding and extending half-life to approximately 5 days. Critically, tirzepatide demonstrates imbalanced and biased agonism: it is a full agonist at GIPR but a partial/biased agonist at GLP-1R compared to native GLP-1.
Dual Receptor Pharmacology
GIPR activation. The glucose-dependent insulinotropic polypeptide receptor (GIPR) is a class B GPCR expressed on pancreatic beta cells, adipose tissue, brain, and bone. In beta cells, GIPR activation enhances glucose-stimulated insulin secretion via cAMP/PKA signalling. In adipose tissue, GIPR signalling has complex effects on lipid metabolism studied in both rodent and human adipocyte models. Central GIPR expression in the hypothalamus and other CNS regions is an active area of research examining its role in energy balance.
GLP-1R activation. As with Semaglutide, GLP-1R activation mediates glucose-dependent insulin secretion, gastric emptying delay, and central appetite suppression. Tirzepatide's GLP-1R agonism is biased towards beta-arrestin-independent pathways compared to semaglutide, a pharmacological difference studied in cellular signalling research.
Research Significance: Incretin Combination Pharmacology
The key research question addressed by tirzepatide studies is whether GIPR co-agonism adds to, is equivalent to, or synergises with GLP-1R agonism. Research has examined this through several approaches: direct comparison with GLP-1R monoagonists (Semaglutide), GIPR knockout models, and GIPR antagonist co-administration studies.
Tirzepatide is a central reference compound for researchers studying incretin pharmacology alongside Retatrutide (which extends dual to triple agonism by adding GCGR activity).
GIP vs GLP-1 Receptor: Key Differences
| Property | GIPR | GLP-1R |
|---|---|---|
| Endogenous ligand | GIP (42aa) | GLP-1 (30aa) |
| G-protein coupling | Gs (primary) | Gs (primary) |
| Beta-arrestin recruitment | Yes | Yes |
| CNS expression | Hypothalamus, other areas | Hypothalamus, NTS, area postrema |
| Adipose tissue expression | High | Low |
| Bone expression | Yes | Limited |
| Tirzepatide activity | Full agonist | Partial/biased agonist |
Frequently Asked Questions
Why is Tirzepatide described as a biased agonist at GLP-1R?
Tirzepatide binds GLP-1R but activates it in a pharmacologically distinct manner from balanced GLP-1R agonists like Semaglutide. Specifically, Tirzepatide shows preferential activation of G-protein (cAMP) signalling over beta-arrestin recruitment at GLP-1R. This means it produces less receptor internalisation and desensitisation than a balanced agonist at equivalent receptor occupancy. Whether this GLP-1R bias contributes to Tirzepatide's distinct metabolic effects compared to Semaglutide is an active area of pharmacological research.
What is the role of central GIPR signalling in research?
For decades, GIPR research focused on pancreatic beta cells and adipose tissue. More recently, GIPR expression has been identified in hypothalamic neurons, area postrema, and other CNS regions involved in energy balance regulation. Some preclinical research suggests that central GIPR signalling may mediate part of the weight-related effects observed with GIPR agonism — potentially synergising with central GLP-1R signalling. This hypothesis has driven interest in characterising brain GIPR pharmacology as a means of understanding Tirzepatide's mechanisms.
How should researchers approach comparative studies between Tirzepatide and Semaglutide?
Key considerations include: receptor selectivity (Tirzepatide acts at both GIPR and GLP-1R, complicating attribution of effects to a single receptor), agonist bias at GLP-1R (which may affect receptor trafficking and downstream signalling differently), concentration selection (functional assay EC50 values differ between the two compounds), and the use of appropriate receptor-specific controls such as GIPR antagonists or GLP-1R antagonists (Exendin(9-39)) to dissect individual receptor contributions.
Published Research References
For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.
Related research peptides: Semaglutide | Retatrutide | IGF-1 LR3